Mbx biosciences reports fourth quarter and full year 2024 financial results and recent corporate highlights

Enrollment complete in phase 2 avail™ trial of canvuparatide in hypoparathyroidism; topline results on track for q3 2025 mbx 1416 phase 2 trial in patients with post-bariatric hypoglycemia expected to begin in 2h 2025 investigational new drug submission anticipated in q2 2025 for mbx 4291 in obesity $262.1 million in cash, cash equivalents and marketable securities as of december 31, 2024; expected to support operations into mid-2027 carmel, ind., march 17, 2025 (globe newswire) -- mbx biosciences, inc. (nasdaq: mbx), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today reported financial results for the fourth quarter and full year ended december 31, 2024, and highlighted recent corporate progress.
MBX Ratings Summary
MBX Quant Ranking